Cencora Appoints New Chairman Effective October 2025

Cencora ( (COR) ) has issued an announcement.

On August 27, 2025, Cencora announced the appointment of D. Mark Durcan as the new Chairman of the Board, effective October 1, 2025. Durcan, who has been a director since 2015 and Lead Independent Director since March 2023, will succeed Steven H. Collis, who will retire at the end of the fiscal year. This leadership transition is expected to support Cencora’s continued growth and leadership in the healthcare industry, leveraging Durcan’s extensive experience in strategic planning and technological innovation.

The most recent analyst rating on (COR) stock is a Hold with a $300.00 price target. To see the full list of analyst forecasts on Cencora stock, see the COR Stock Forecast page.

Spark’s Take on COR Stock

According to Spark, TipRanks’ AI Analyst, COR is a Neutral.

Cencora’s overall stock score reflects a balance of strengths and challenges. Strong earnings performance and strategic financial adjustments are positive, but high leverage and valuation concerns weigh on the score. Technical indicators provide a neutral outlook, while the company’s modest dividend yield offers limited investor income.

To see Spark’s full report on COR stock, click here.

More about Cencora

Cencora is a leading global pharmaceutical solutions organization focused on enhancing the lives of people and animals worldwide. The company collaborates with pharmaceutical innovators to optimize market access to therapies and is trusted by care providers for the secure and reliable delivery of pharmaceuticals, healthcare products, and solutions. Cencora is ranked #10 on the Fortune 500 and #18 on the Global Fortune 500, with over $290 billion in annual revenue.

Average Trading Volume: 1,301,846

Technical Sentiment Signal: Strong Buy

Current Market Cap: $56.17B

For detailed information about COR stock, go to TipRanks’ Stock Analysis page.